The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows specific addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to attend traditional treatment clinics. This change permits these qualified doctors to use telemedicine for patient care and requires that the methadone be in a liquid or dispersible tablet form. While the bill maintains existing clinic-based treatment options, it streamlines access by removing the need for pharmacies to obtain separate registrations to dispense the medication. The law also mandates that patients sign informed consent forms explaining how privacy rules differ between clinic and pharmacy settings, and it requires the Drug Enforcement Administration to report on the program's progress to Congress every year.
This resolution condemns all forms of hate, including racism, antisemitism, transphobia, and xenophobia, while highlighting recent statistics on hate crimes affecting various communities. It calls for comprehensive federal and state policies to prevent hate crimes through education and intervention, as well as support for victims through legal aid and mental health resources. The measure also advocates for funding programs that are culturally accessible to vulnerable groups, such as immigrants and LGBTQIA+ individuals, and reaffirms the government's commitment to maintaining an inclusive democracy.
This bill creates a new program to speed up the approval process for specific over-the-counter drugs that could offer significant public health benefits. Drug companies can request this "priority" status for new medications intended for conditions that currently require a prescription, provided the drugs are new or contain active ingredients never seen in nonprescription products. If approved, the FDA will assign senior staff and specialized teams to work closely with the companies, offering faster guidance and more efficient review schedules while maintaining the same safety and effectiveness standards. The program includes a requirement to publish a list of eligible health conditions and will expire in September 2032 unless renewed by Congress.
The More Paid Leave for More Americans Act creates a federal grant program to help states establish or improve paid leave systems that offer up to six weeks of paid time off for reasons like illness, family care, or bonding. To receive funding, states must create a partnership with private entities to manage the program and agree to a national network that standardizes rules and technology across different states. The bill sets specific requirements for benefit amounts, such as providing at least 67 percent of an employee's weekly pay for low-income workers, and allows grants of up to $8 million per state to cover startup costs and ongoing operations. Additionally, the legislation authorizes funding for a national organization to build a shared technology system that helps workers apply for benefits regardless of which states they have worked in.
The Water Emergency and Technical Assistance Act of 2026 establishes a funding mechanism to help states and water treatment facilities respond to emergencies that pose a significant danger to public health, such as sewer overflows or cybersecurity incidents. Under this bill, the Environmental Protection Agency Administrator can provide grants and technical assistance for activities that prevent or mitigate health risks but would be too costly for ratepayers to fund on their own. The legislation authorizes $50 million annually from fiscal years 2027 through 2031 to support these emergency efforts and also increases the existing funding for drinking water emergencies during the same period.
This bill establishes the Native Children's Commission Implementation Act of 2026 to improve health, education, and safety outcomes for Native American, Alaska Native, and Native Hawaiian children and families. It creates several new advisory committees within federal agencies to provide ongoing guidance on issues such as juvenile justice, maternal health, substance abuse, and environmental protection. The legislation also authorizes grants and pilot programs to expand access to mental health services, increase the perinatal workforce, support Native language schools, and provide housing assistance for homeless youth and families. Additionally, it modifies existing laws to allow Tribes greater flexibility in administering nutrition and child care programs while ensuring they receive adequate funding for administrative costs.
The Mamas First Act expands Medicaid coverage to include prenatal, labor, and postpartum care provided by doulas, midwives, tribal midwives, and lactation support providers. To qualify for this coverage, these professionals must meet specific certification, training, or recognition standards, such as doulas having continuing education and references from former clients or healthcare providers. The bill also prohibits Medicaid programs from charging copayments or deductibles for these essential services. These changes are scheduled to take effect on January 1, 2027, aiming to improve maternal health outcomes by increasing access to supportive care.
The Maternal Access to Treatment Act of 2026 requires the Bureau of Prisons to offer medication-assisted treatment to pregnant inmates addicted to opioids. This provision ensures that pregnant women in federal custody have access to medical care for opioid use disorder, unless they explicitly choose to decline the treatment while remaining mentally competent. The bill directly affects the Bureau of Prisons and pregnant incarcerated women by mandating the availability of this specific medical service.
This bill, known as the Medicare Premiums Reduction Act of 2026, aims to lower the income thresholds used to calculate extra monthly premiums for Medicare Part B. It directly affects Medicare beneficiaries whose income exceeds specific limits, currently set at $85,000 for individuals and $170,000 for couples, by raising these limits to $171,000 and $205,000 respectively for the years 2027 and beyond. The legislation also adjusts the percentage of income used to determine these premiums, introducing new higher rates for those with modified adjusted gross income exceeding $205,000. By modifying the Social Security Act, the bill ensures that fewer high-income earners will be subject to the additional Part B surcharge starting in 2027.
The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release records of specific agreements between the federal government and major drug manufacturers starting in 2025. These agreements must include provisions such as offering lower drug prices based on international rates, providing discounts through government platforms like TrumpRx, or receiving special exemptions from import duties and regulatory reviews. While the bill mandates that most documents be made available in a searchable format, it allows the government to withhold only specific confidential pricing details if legally required by foreign laws or court orders, provided a justification is published. Additionally, the law directs the Congressional Budget Office and the Government Accountability Office to analyze the economic and budgetary impacts of these deals, including effects on Medicare, Medicaid, and drug competition.
